"Moraxellaceae Infections"[MAJR] - Search Results

Year	Number of Results
1950	1
1953	1
1955	1
1956	3
1957	2
1958	2
1959	3
1960	3
1961	5
1962	2
1963	1
1964	2
1966	2
1967	4
1968	9
1969	6
1970	3
1971	10
1972	8
1973	3
1974	1
1975	5
1976	2
1977	11
1978	12
1979	11
1980	13
1981	13
1982	15
1983	11
1984	5
1985	11
1986	8
1987	21
1988	15
1989	22
1990	25
1991	12
1992	13
1993	28
1994	22
1995	33
1996	18
1997	27
1998	23
1999	45
2000	55
2001	46
2002	47
2003	60
2004	83
2005	98
2006	115
2007	143
2008	169
2009	178
2010	195
2011	256
2012	254
2013	293
2014	310
2015	293
2016	279
2017	253
2018	268
2019	285
2020	246
2021	235
2022	231
2023	130
2024	45

1

Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections.

El-Ghali A, Kunz Coyne AJ, Caniff K, Bleick C, Rybak MJ. El-Ghali A, et al. Pharmacotherapy. 2023 Jun;43(6):502-513. doi: 10.1002/phar.2802. Epub 2023 May 23. Pharmacotherapy. 2023. PMID: 37052117 Review.

2

Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.

Shields RK, Paterson DL, Tamma PD. Shields RK, et al. Clin Infect Dis. 2023 May 1;76(Suppl 2):S179-S193. doi: 10.1093/cid/ciad094. Clin Infect Dis. 2023. PMID: 37125467 Free PMC article. Review.

3

Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Wong D, et al. Clin Microbiol Rev. 2017 Jan;30(1):409-447. doi: 10.1128/CMR.00058-16. Clin Microbiol Rev. 2017. PMID: 27974412 Free PMC article. Review.

4

Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models.

McConnell MJ, Actis L, Pachón J. McConnell MJ, et al. FEMS Microbiol Rev. 2013 Mar;37(2):130-55. doi: 10.1111/j.1574-6976.2012.00344.x. Epub 2012 Jun 18. FEMS Microbiol Rev. 2013. PMID: 22568581 Free article. Review.

5

Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Bergogne-Bérézin E, Towner KJ. Bergogne-Bérézin E, et al. Clin Microbiol Rev. 1996 Apr;9(2):148-65. doi: 10.1128/CMR.9.2.148. Clin Microbiol Rev. 1996. PMID: 8964033 Free PMC article. Review. No abstract available.

6

How to treat severe Acinetobacter baumannii infections.

Bouza E, Muñoz P, Burillo A. Bouza E, et al. Curr Opin Infect Dis. 2023 Dec 1;36(6):596-608. doi: 10.1097/QCO.0000000000000974. Epub 2023 Sep 26. Curr Opin Infect Dis. 2023. PMID: 37930071 Review.

7

Managing Acinetobacter baumannii infections.

Garnacho-Montero J, Timsit JF. Garnacho-Montero J, et al. Curr Opin Infect Dis. 2019 Feb;32(1):69-76. doi: 10.1097/QCO.0000000000000518. Curr Opin Infect Dis. 2019. PMID: 30520737 Review.

8

Community-acquired Acinetobacter infections.

Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. Falagas ME, et al. Eur J Clin Microbiol Infect Dis. 2007 Dec;26(12):857-68. doi: 10.1007/s10096-007-0365-6. Eur J Clin Microbiol Infect Dis. 2007. PMID: 17701432 Review.

9

Acinetobacter: a perspective.

Allen DM, Wong SY. Allen DM, et al. Singapore Med J. 1990 Dec;31(6):511-4. Singapore Med J. 1990. PMID: 2281342 Review. No abstract available.

10

Resistance mechanisms of tigecycline in Acinetobacter baumannii.

Sun C, Yu Y, Hua X. Sun C, et al. Front Cell Infect Microbiol. 2023 May 9;13:1141490. doi: 10.3389/fcimb.2023.1141490. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37228666 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

4,504 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

4,504 results

Results by year